We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
4 Healthcare Mutual Funds to Buy Amid Market Volatility
Read MoreHide Full Article
In a market facing continued volatility over a long period of time, healthcare is a sector that usually does well. Investors, who adopt a risk-off attitude, bank on the defensive nature of the sector. The regular demand for healthcare services is not dependent on the peaks and troughs of a market, and hence, provides protection against market volatility. The sector also seems lucrative for investors looking for a steady cash flow, because pharmaceutical companies are known to offer regular dividends.
Health spending in the United States is projected to grow at an average annual rate of 5.4% for 2019-2028 and to reach $6.2 trillion by 2028. Even as the industry faces labor shortages and recessionary pressures in the post-pandemic world marked by a European war, it would grow at a higher rate than the overall economy.
There might be a shift toward government segments and institutions more than private players, with patients and customers trying to maximize the advantages of social security, but demand would not go down. Also, artificial intelligence is slated to revolutionize the sector in the areas of diagnosis, treatment, and monitoring of patients, eventually reducing costs and making the services affordable.
Healthcare has seen growth in the ETF market in 2023. The S&P 500 Select Sector SPDR for Healthcare (XLV) grew 4.1% over the past year as of Apr 30, 2023. In April itself, the sector grew 3.1% and is poised to grow throughout 2023. The sector may be off its pandemic period peak, but will remain resilient and continue to grow in the coming years. To give an idea, in 2021, the United States spent 18.3% of its GDP on healthcare.
Hence, astute investors should invest in healthcare mutual funds at present. Mutual funds, in general, reduce transaction costs and diversify portfolios without an array of commission charges that are mostly associated with stock purchases (read more: Mutual Funds: Advantages, Disadvantages, and How They Make Investors Money).
We have thus selected four such healthcare mutual funds that boast a Zacks Mutual Fund Rank #1 (Strong Buy), 2 (Buy), have positive three-year and five-year annualized returns, minimum initial investments within $5000, and carry a low expense ratio.
Schwab Health Care Fund (SWHFX - Free Report) primarily invests in equity securities issued by healthcare companies. SWHFX usually invests the majority of its net assets in these securities. The healthcare sector includes pharmaceutical and biotech companies, healthcare facilities operations, medical product manufacturers and suppliers, medical providers, and medical services firms.
Wei Li has been the lead manager of SWHFX since June 2013. The fund has 5.5% of its portfolio invested in UnitedHealth Group, 4.9% in Merck, and 4.8% in Johnson & Johnson.
SWHFX’s 3-year and 5-year annualized returns are 10% and 9.9%, respectively. Its net expense ratio is 0.80% compared to the category average of 1.03%. SWHFX has a Zacks Mutual Fund Rank #1. To see how this fund performed compared to its category, and other 1 and 2 Ranked Mutual Funds, please click here.
Putnam Global Health Care Fund (PHSTX - Free Report) primarily invests in common stocks of large and mid-cap healthcare companies. PHSTX invests in companies that its advisors believe have favorable investment potential.
Michael Maguire has been the lead manager of PHSTX since November 2016. The fund has 9.4% of its portfolio invested in UnitedHealth Group, 6.6% in AstraZeneca, and 6.1% in Merck.
PHSTX’s 3-year and 5-year annualized returns are 10.1% and 11.2%, respectively. Its net expense ratio is 0.53% compared to the category average of 1.03%. PHSTX has a Zacks Mutual Fund Rank #2.
Janus Henderson Global Life Sciences Fund (JNGLX - Free Report) primarily invests in equity securities issued by companies engaged in life sciences orientation.
Andrew Acker has been the lead manager of JNGLX since April 2007. The fund has 6.6% of its portfolio invested in UnitedHealth Group, 4.4% in AstraZeneca and 3.9% in AbbVie.
JNGLX’s 3-year and 5-year annualized returns are 11.3% and 11.7%, respectively. Its net expense ratio is 0.80% compared to the category average of 1.03%. JNGLX has a Zacks Mutual Fund Rank #1.
Vanguard Health Care Fund (VGHCX - Free Report) primarily invests in stocks of companies principally engaged in the development, production, or distribution of products and services in the healthcare industry. VGHCX also invests a significant portion of its assets in foreign stocks.
Jean M. Hynes has been the lead manager of VGHCX since May 2008. The fund has 6.2% of its portfolio invested in UnitedHealth Group, 5.5% in Eli Lilly and 5.4% in AstraZeneca.
VGHCX’s 3-year and 5-year annualized returns are 10% and 10.9%, respectively. Its net expense ratio is 0.34% compared to the category average of 1.03%. VGHCX has a Zacks Mutual Fund Rank #1.
Want key mutual fund info delivered straight to your inbox?
Zacks' free Fund Newsletter will brief you on top news and analysis, as well as top-performing mutual funds, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
4 Healthcare Mutual Funds to Buy Amid Market Volatility
In a market facing continued volatility over a long period of time, healthcare is a sector that usually does well. Investors, who adopt a risk-off attitude, bank on the defensive nature of the sector. The regular demand for healthcare services is not dependent on the peaks and troughs of a market, and hence, provides protection against market volatility. The sector also seems lucrative for investors looking for a steady cash flow, because pharmaceutical companies are known to offer regular dividends.
Health spending in the United States is projected to grow at an average annual rate of 5.4% for 2019-2028 and to reach $6.2 trillion by 2028. Even as the industry faces labor shortages and recessionary pressures in the post-pandemic world marked by a European war, it would grow at a higher rate than the overall economy.
There might be a shift toward government segments and institutions more than private players, with patients and customers trying to maximize the advantages of social security, but demand would not go down. Also, artificial intelligence is slated to revolutionize the sector in the areas of diagnosis, treatment, and monitoring of patients, eventually reducing costs and making the services affordable.
Healthcare has seen growth in the ETF market in 2023. The S&P 500 Select Sector SPDR for Healthcare (XLV) grew 4.1% over the past year as of Apr 30, 2023. In April itself, the sector grew 3.1% and is poised to grow throughout 2023. The sector may be off its pandemic period peak, but will remain resilient and continue to grow in the coming years. To give an idea, in 2021, the United States spent 18.3% of its GDP on healthcare.
Hence, astute investors should invest in healthcare mutual funds at present. Mutual funds, in general, reduce transaction costs and diversify portfolios without an array of commission charges that are mostly associated with stock purchases (read more: Mutual Funds: Advantages, Disadvantages, and How They Make Investors Money).
We have thus selected four such healthcare mutual funds that boast a Zacks Mutual Fund Rank #1 (Strong Buy), 2 (Buy), have positive three-year and five-year annualized returns, minimum initial investments within $5000, and carry a low expense ratio.
Schwab Health Care Fund (SWHFX - Free Report) primarily invests in equity securities issued by healthcare companies. SWHFX usually invests the majority of its net assets in these securities. The healthcare sector includes pharmaceutical and biotech companies, healthcare facilities operations, medical product manufacturers and suppliers, medical providers, and medical services firms.
Wei Li has been the lead manager of SWHFX since June 2013. The fund has 5.5% of its portfolio invested in UnitedHealth Group, 4.9% in Merck, and 4.8% in Johnson & Johnson.
SWHFX’s 3-year and 5-year annualized returns are 10% and 9.9%, respectively. Its net expense ratio is 0.80% compared to the category average of 1.03%. SWHFX has a Zacks Mutual Fund Rank #1. To see how this fund performed compared to its category, and other 1 and 2 Ranked Mutual Funds, please click here.
Putnam Global Health Care Fund (PHSTX - Free Report) primarily invests in common stocks of large and mid-cap healthcare companies. PHSTX invests in companies that its advisors believe have favorable investment potential.
Michael Maguire has been the lead manager of PHSTX since November 2016. The fund has 9.4% of its portfolio invested in UnitedHealth Group, 6.6% in AstraZeneca, and 6.1% in Merck.
PHSTX’s 3-year and 5-year annualized returns are 10.1% and 11.2%, respectively. Its net expense ratio is 0.53% compared to the category average of 1.03%. PHSTX has a Zacks Mutual Fund Rank #2.
Janus Henderson Global Life Sciences Fund (JNGLX - Free Report) primarily invests in equity securities issued by companies engaged in life sciences orientation.
Andrew Acker has been the lead manager of JNGLX since April 2007. The fund has 6.6% of its portfolio invested in UnitedHealth Group, 4.4% in AstraZeneca and 3.9% in AbbVie.
JNGLX’s 3-year and 5-year annualized returns are 11.3% and 11.7%, respectively. Its net expense ratio is 0.80% compared to the category average of 1.03%. JNGLX has a Zacks Mutual Fund Rank #1.
Vanguard Health Care Fund (VGHCX - Free Report) primarily invests in stocks of companies principally engaged in the development, production, or distribution of products and services in the healthcare industry. VGHCX also invests a significant portion of its assets in foreign stocks.
Jean M. Hynes has been the lead manager of VGHCX since May 2008. The fund has 6.2% of its portfolio invested in UnitedHealth Group, 5.5% in Eli Lilly and 5.4% in AstraZeneca.
VGHCX’s 3-year and 5-year annualized returns are 10% and 10.9%, respectively. Its net expense ratio is 0.34% compared to the category average of 1.03%. VGHCX has a Zacks Mutual Fund Rank #1.
Want key mutual fund info delivered straight to your inbox?
Zacks' free Fund Newsletter will brief you on top news and analysis, as well as top-performing mutual funds, each week. Get it free >>